Small molecule inhibitors of galectin-3
Small molecule inhibitors of Gal-3 are developed to address the limitations of current treatments by effectively inhibiting Gal-3 activity, offering therapeutic benefits in fibrosis, cancer, and inflammation, and enhancing immunotherapy efficacy.
Patent Information
- Application Number
- JP2021559883
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-10
- Filing Date
- 2020-04-08
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-04-08
AI Technical Summary
Current treatments for conditions involving galectin-3 (Gal-3) are inadequate in effectively modulating its activity to address inflammation, fibrosis, and cancer progression, particularly in combination with immunotherapy.
Development of small molecule inhibitors of Gal-3, including specific compounds and their pharmaceutically acceptable salts, which can be administered to treat various medical conditions by inhibiting Gal-3 activity.
The small molecule inhibitors effectively target and inhibit Gal-3, providing therapeutic benefits in treating fibrosis, cancer, and inflammatory diseases, as well as improving outcomes in combination with immunotherapy.
Smart Images

Figure 0007577682000001 
Figure 0007577682000002 
Figure 0007577682000003
Abstract
Description
[Technical field]
[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Application No. 62 / 831,753, filed April 10, 2019, which is incorporated by reference in its entirety. [Background technology]
[0002] Galectin-3 (Gal-3) is a β-galactoside-binding lectin of approximately 30 KDa (Cell 76: 597-598) that is involved in the regulation of inflammatory and fibrotic processes (Immunological Reviews 230: 160-171). Under conditions of uncontrolled inflammation and fibrosis, Gal-3 promotes fibroblast proliferation and transformation and mediates collagen production (Circulation 110:3121-3128).
[0003] Gal-3 is localized in many cellular sites, such as the cytoplasm, nucleus, and cell surface. Gal-3 is also secreted into the bloodstream by various cells, primarily macrophages and monocytes (J Pharmacol Exp Ther 351:336-343). There are multiple lines of evidence in the literature supporting the involvement of Gal-3 in the progression of fibrosis in multiple organs, such as the lung (Am J. Respir. Crit. Care Med. 185: 537-546), liver (PNAS 103:5060-5065), and kidney (Am. J. Pathol. 172:288-298). Gal-3 is also known as a biomarker for heart failure, and it has been shown that modulation of Gal-3 may be used to treat heart failure (Curr. Heart Fail. Rep. 7:1-8). Gal-3 is involved in cell proliferation and differentiation, which plays a crucial role in angiogenesis, apoptosis pathway, and metastasis pathway (Galectin-3C: Human Lectin for Treatment of Cancer. ACS Symposium Series, Vol. 1115. Chapter 12, 195-23), so regulating Gal-3 can be used to treat cancer. Recently, it has been proven that Gal-3 inhibitors can be used in combination with immunotherapy to achieve good results (Galectin Therapeutics. Press Release, February 7, 2017).
[0004] Several publications and patent applications describe inhibitors of Gal-3 synthesis that are being investigated as antifibrotic agents. Recent examples of such studies include WO2005113568, WO2005113569, US2014067986, WO2014067986, WO2017080971, WO2016120403, US20140099319, and WO2014067986 and WO2018209255.
[0005] (Details of the invention) The present disclosure relates to compounds of the invention that inhibit Gal-3, including pharma- ceutical acceptable salts, compositions comprising such compounds, and methods of using and preparing such compounds and compositions.
[0006] In a first aspect, the present invention relates to, inter alia, a compound of formula (I) or (II): [ka] [In the formula, X is independently selected from -C(O)-, -CH2-, and -CH2C(O)-; Ar 1 is independently phenyl or naphthyl; where each ring is selected from the group consisting of cyano, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, and C 1-4 substituted with 1 to 5 substituents selected from haloalkoxy; R 1 are independently H, C 1-4 Alkyl, and C 1-4 haloalkyl; R 2 are independently H or C 1-4 is alkyl; R 3 are independently 2 , -(CH2) 1-2 Ar 2 , and -CH2CH2NR 4 Ar 2 Selected from; Ar 2 are independently phenyl, [ka] and 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R 5 ), O, and S; each ring is selected from OH, cyano, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4Alkoxy, C 1-4 Haloalkoxy, N(C 1-4 Alkyl)2, -SO2(C 1-4 Alkyl), -OPh, -OBn, C 3-6 Cycloalkyl; and cyano, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, -NH2, -NH(C 1-4 alkyl), and -N(C 1-4 phenyl substituted with 0-1 substituents selected from alkyl); R 4 are independently H or C 1-4 is alkyl; and R 5 are independently H or C 1-4 is alkyl] or a pharma- ceutically acceptable salt thereof.
[0007] In a second embodiment within the first embodiment, a compound of formula (Ia): [ka] or a pharma- ceutically acceptable salt thereof.
[0008] In a third embodiment within the first or second embodiment, wherein Ar 1 is independently phenyl or naphthyl; wherein each ring is selected from the group consisting of cyano, halogen, C 1-4 Alkyl, and C 1-4 substituted with 1 to 3 substituents selected from alkoxy; R 1 are independently H or C 1-4 is alkyl; and Ar 2 are independently phenyl, [ka] , pyridinyl, benzothiophenyl, benzothiazolyl, N-(C 1-4 each ring is selected from OH, cyano, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, N(C 1-4 Alkyl)2, -SO2(C 1-4 substituted with 0 to 4 substituents selected from -alkyl, -OPh, and -OBn; A compound of formula (I) or (Ia), or a pharma- ceutically acceptable salt thereof.
[0009] In a fourth embodiment within the scope of the first to third embodiments, Ar 1 is, independently, [ka] is selected from.
[0010] In a fifth embodiment within the scope of the first to fourth embodiments, R 3 But independently, Ar 2 , -(CH2) 1-2 Ar 2 , and -CH2CH2NR 4 Ar 2 Selected from; Ar 2 But independently, [ka] is selected from.
[0011] In a sixth embodiment within the scope of the first to fifth embodiments, R 1 is independently H or CH3; R 2 is independently selected from H, CH3, -CH2CH3, and -CH(CH3)2; and R 4are independently H or CH3.
[0012] In another embodiment within the scope of any one of the first to sixth embodiments, R 1 is H.
[0013] In another embodiment, R 1 is CH3.
[0014] In another aspect, the present invention provides a compound selected from the Examples, or a pharma- ceutically acceptable salt thereof.
[0015] In another aspect, the present invention provides a compound selected from Examples 1-44 and B1-B25, or a pharma- ceutically acceptable salt thereof.
[0016] In another aspect, the present invention provides a compound selected from Examples 1-44, or a pharma- ceutically acceptable salt thereof.
[0017] In another aspect, the present invention provides a compound selected from Examples B1-B25, or a pharma- ceutically acceptable salt thereof.
[0018] Unless otherwise stated, the above terms have the following meanings: "Alkyl" means a straight or branched chain alkyl group having 1 to 6 carbons. "Cycloalkyl" means a monocyclic ring having 3 to 7 carbons. Terms for hydrocarbon moieties (e.g., alkoxy) include straight and branched chain isomers of hydrocarbon moieties having 1 to 6 carbons. "Halo" includes fluoro, chloro, bromo, and iodo. "Haloalkyl" and "haloalkoxy" include all halogenated isomers from monohalogen to perhalogen. "Aryl" means a monocyclic or bicyclic aromatic ring system having 5 to 12 carbon atoms in which one or both rings are aromatic. Representative examples of aryl groups include, but are not limited to, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl. "Heteroaryl" means a 5-7 membered monocyclic or 8-11 membered bicyclic aromatic ring system having 1 to 5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. If no bond position is specified, bond may occur at any suitable position as understood by those skilled in the art. The combination of substituents and bond patterns are only those that result in stable compounds as understood by those skilled in the art. Parentheses and multiple parenthetical terms are intended to clarify the bond relationship for those skilled in the art. For example, a term such as ((R) alkyl) refers to an alkyl substituent further substituted with a substituent R.
[0019] The present invention includes all pharma- ceutically acceptable salt forms of the compound. A pharma-ceutically acceptable salt is one in which the counter ion does not contribute significantly to the bioactivity or toxicity of the compound, and therefore functions as a pharmacological equivalent. These salts can be prepared according to common organic chemistry techniques using commercially available reagents. Some anionic salt forms include acetate, acistatrate, besylate, bromide, chloride, citrate, fumarate, glucuronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinafoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc salts.
[0020] Some of the compounds of the present invention exist in stereoisomeric forms.The present invention encompasses all stereoisomeric forms of the compounds, including enantiomers and diastereomers.Methods for producing and separating stereoisomers are known in the art.The present invention encompasses all tautomeric forms of the compounds.The present invention encompasses atropisomers and rotamers.
[0021] The present invention is intended to include all isotopes of atoms contained in the compounds of the present invention. Isotopes include atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include 13 C and 14Isotopically labeled compounds of the present invention can be prepared by conventional techniques generally known to those skilled in the art, or by methods similar to those described herein, using appropriate isotopically labeled reagents instead of non-labeled reagents used elsewhere. Such compounds can have a variety of potential uses, for example, as standards and reagents in determining biological activity. In the case of stable isotopes, such compounds can have the ability to advantageously modify biological, pharmacological, or pharmacokinetic properties.
[0022] (Biological Methods) Gal-3 HTRF assay Assay Buffer Composition: 25 mM HEPES, 100 mM NaCl, 0.005% Tween 20, 0.05% BSA prepared in sterile water (all reagents purchased from Sigma). control: Positive control: 100% DMSO (1 μL) + His-tagged hGal-3 (20 μL) + B-ASF (20 μL) + anti-His terbium antibody (5 μL) + Strep d2 antibody (5 μL) Negative control: 100% DMSO (1 μL) + His-tagged hGal-3 (20 μL) + anti-His terbium antibody (5 μL) + Strep d2 antibody (5 μL) [Table 1] protocol: Gal-3 assays were performed in triplicate in 384 white OptiPlates at room temperature with gentle rocking at 250-300 rpm. His-tagged recombinant human Gal-3 (hGal-3) and B-ASF solutions were prepared in working solutions diluted 2.525-fold from stock solutions. hGal-3 (20 μL, 15 nM) and B-ASF (20 μL, 15 nM) prepared in working solutions were added to the plates. For negative controls, only hGal-3 was added. For compounds dissolved in 100% DMSO, concentrations ranging from 50-fold dilutions of working solutions were prepared. A portion of compound (1 μL) was added to wells previously incubated with 20 μL hGal-3 per well for 30 min. 20 μL B-ASF was then added and incubated for an additional hour. To detect the signal, 5 μL (final concentration 1.0 nM) of terbium-labeled anti-His antibody was added and incubated for 30 min, followed by 5 μL (final concentration 20 nM) of streptavidin d2 and further incubation for 1 h. The assay signal was detected on an Envision 2104 Multilabel Reader using the HTRF screen protocol (excitation wavelength = 340 nm, emission wavelength = 615 nm / 665 nm). Data were analyzed using Toolset and Curve Master. Results (IC 50 (μM) are given in the Experimental Section.
[0023] Gal-3 ELISA assay material: 1. Coating buffer: Phosphate-buffered saline (1x) - PBS This solution was prepared by dissolving one pack of PBS purchased from Sigma Aldrich (catalog number: P3813-5x10Pak) in 1 L of Milli-Q water. 2. Asialofetuin: from fetal bovine serum, type II, Sigma Aldrich (Cat. No.: A1908-50MG) 3. Fetal Bovine Serum: Invitrogen (Cat. No.: 26400-044-500mL) 4. Tween-20: Sigma Aldrich (Cat. No.: P1379-250mL) 5. OptEIA Enzyme Reagent Streptavidin-HRP: BD (Cat. No.: 554066) 6. Sulfuric acid: Sigma Aldrich (Cat. No.: 25,810-5) 7. Paraformaldehyde: Sigma Aldrich (Cat. No.: P6148-500G) 8. TMB Substrate: BD Biosciences (Cat. No.: 555214) 9. Biotinylated hGal-3-A 0.82 mg / mL stock solution (28.6 kDa, 28.6713 µM): Synthesized in-house by the Proteomics Group This solution was used for the titration. 10. TD-139(EXT-001109-01-001): Small molecule indoor synthesis This was used as an internal control for small molecule screening in an hGal-3 normalized binding assay.
[0024] A. Protocol: a. Coating of plates: ASF was prepared at a concentration of 15 nM in 1x PBS, and injected into a 96-well flat-bottom nunc plate (Nunc Immunoplate, Maxisorp, Catalog No.: 439454) according to the plate map, sealed with a top seal, and incubated overnight at 4°C. b. Fixing and blocking the plates: On the day of the assay, the coating solution was removed and the plates were fixed with 100 μL of 2% paraformaldehyde solution and incubated at 37°C for 30 min. They were washed three times with 300 μL of washing buffer (PBS containing 0.05% Tween-20), dried and then moved onto blocking. The plates were blocked with 10% FBS and incubated for 1 h at room temperature. The plates were then washed three times with 300 μL of washing buffer (PBS containing 0.05% Tween-20).
[0025] B. Incubation: After the washed plates were dried, 100 μL of test compounds were added to the plates (pre-incubated with 15 nM human galectin-3 (hGal-3) or mouse galectin-3 (mGal-3) at room temperature for 1 hour) at various concentrations as indicated on the plate map. Duplicate plates were run to ensure accuracy and reproducibility of the data. The plates were incubated for 1 hour at room temperature, washed five times with wash buffer, dried, and 100 μL of streptavidin-HRP (1:1000 dilution) was added, incubated for 1 hour at room temperature, and washed seven times with wash buffer.
[0026] C. Detection: After the washed plates were dried, 100 μL of TMB substrate was added to each well and incubated for 15 min at room temperature, after which the reaction was stopped with 2N sulfuric acid and the plates were read on a SpectraMax (450 nm).
[0027] result: After normalization with the average control value, the output values (OD) obtained against the control wells were plotted and the common logarithm of the 50% inhibitory concentration of the program compound (Log IC 50 ) was analyzed.
[0028] summary: IC of program compounds 50 The values are shown in the report (attached in Excel format obtained from Curve master editing). In the control plate TD-139, hGal-3 and mGal-3 had IC values of 10.3 nM and 108.12 nM, respectively. 50 The same was plotted on a semi-logarithmic graph.
[0029] Pharmaceutical Compositions and Methods of Use The compounds of the present invention inhibit Gal-3. Accordingly, another aspect of the present invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention, or a pharma- ceutical acceptable salt thereof, and a pharma- ceutical acceptable carrier.
[0030] Another aspect of the invention is directed to the treatment of fibrosis of organs (e.g., liver, kidney, lung, heart, and skin), liver diseases and conditions (e.g., acute hepatitis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, liver regeneration failure, nonalcoholic steatohepatitis (NASH), liver dysfunction, and liver blood flow disorders), cell proliferative disorders, and cancer diseases (e.g., solid tumors, solid tumor metastases, angiofibromas, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL), and wet metastasis of cancer cells), inflammatory diseases and conditions (e.g., psoriasis, nephropathy, and pneumonia), gastrointestinal diseases and conditions (e.g., irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and abnormal pancreatic secretion), kidney diseases and conditions, urinary tract-related diseases and conditions (e.g., and / or a combination of the compounds of the present invention, comprising a compound selected from the group consisting of urinary tract disease and conditions (e.g., benign prostatic hyperplasia, or neurogenic bladder-related diseases, spinal tumors, herniated discs, spinal canal stenosis, and diabetes-related conditions), lower urinary tract diseases and conditions (e.g., lower urinary tract obstruction), lower urinary tract inflammatory diseases and conditions (e.g., dysuria and frequent urination), pancreatic diseases and conditions, angiodysplasia-related diseases and conditions (e.g., arterial occlusive disease), scleroderma, brain-related diseases and conditions (e.g., cerebral infarction and cerebral hemorrhage), neuropathic pain and peripheral neuropathy, eye diseases and conditions (e.g., age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreoretinopathy (PVR), cicatricial pemphigoid, and glaucoma filtration surgery scars).
[0031] Another aspect of the invention is a method for treating renal fibrosis, pulmonary fibrosis, hepatic fibrosis, arterial fibrosis and systemic sclerosis, comprising administering to a patient a compound of the invention.
[0032] Another aspect of the invention is a method for treating fibrosis in an organ (eg, liver, kidney, lung, heart and skin) comprising administering to a patient a compound of the invention.
[0033] Another aspect of the invention is a method for treating liver diseases and conditions (e.g., acute hepatitis, chronic hepatitis, liver fibrosis, cirrhosis, portal hypertension, liver regeneration failure, nonalcoholic steatohepatitis (NASH), liver dysfunction, and impaired hepatic blood flow) comprising administering to a patient a compound of the invention.
[0034] Another aspect of the invention is a method for treating cell proliferative disorders and cancer diseases (e.g., solid tumors, metastases of solid tumors, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL) and invasive metastasis of cancer cells), comprising administering to a patient a compound of the invention.
[0035] Another aspect of the invention is a method for treating inflammatory diseases and conditions (eg, psoriasis, nephropathy, and pneumonia) comprising administering to a patient a compound of the invention.
[0036] Another aspect of the invention is a method for treating diseases and conditions of the gastrointestinal tract (e.g., irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and pancreatic secretory disorders) comprising administering to a patient a compound of the invention.
[0037] Another aspect of the invention is a method for treating kidney diseases and conditions comprising administering to a patient a compound of the invention.
[0038] Another aspect of the invention is a method for treating diseases and conditions associated with the urinary tract, such as benign prostatic hyperplasia, or conditions related to neurogenic bladder, spinal tumors, herniated discs, spinal stenosis, and conditions resulting from diabetes, comprising administering to a patient a compound of the invention.
[0039] Another aspect of the invention is a method for treating diseases and conditions of the lower urinary tract (e.g., lower urinary tract obstruction), inflammatory diseases and conditions of the lower urinary tract (e.g., dysuria and frequent urination), comprising administering to a patient a compound of the invention.
[0040] Another aspect of the invention is a method for treating diseases and conditions of the pancreas comprising administering to a patient a compound of the invention.
[0041] Another aspect of the invention is a method for treating angiodysplasia-related diseases and conditions (eg, arterial occlusive disease) comprising administering to a patient a compound of the invention.
[0042] Another aspect of the invention is a method for treating brain-related diseases and conditions (eg, cerebral infarction and cerebral hemorrhage) comprising administering to a patient a compound of the invention.
[0043] Another aspect of the invention is a method for treating neuropathic pain and peripheral neuropathy comprising administering to a patient a compound of the invention.
[0044] Another aspect of the invention is a method for treating ocular diseases and conditions (e.g., age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreoretinopathy (PVR), cicatricial pemphigoid, and glaucoma filtration surgery scars) comprising administering to a patient a compound of the invention.
[0045] The compounds of the present invention may be used in the treatment and / or prevention of pathologies in which Gal-3 is implicated.
[0046] The compounds of the present invention may be used in the manufacture of a medicament for the treatment and / or prophylaxis of conditions in which inhibition of Gal-3 bioactivity is useful (e.g., diseases involving the Gal-3 receptor), in which inhibition of Gal-3 bioactivity is involved in the etiology or pathology of the disease, or is associated with at least one symptom of the disease.
[0047] The compounds of the present invention may be used alone, in combination with other compounds of the present invention, or in combination with one or more, preferably one to two, other drugs.
[0048] "Therapeutically effective amount" means the amount of drug required to provide a patient with meaningful improvement as understood by one with expertise in the pain field.
[0049] "Patient" means a person suffering from pain and who is deemed by a professional in the field to be suitable for treatment.
[0050] The terms "treatment," "therapy," "regimen," and related terms understood by those skilled in the art are used.
[0051] The compound of the present invention is generally provided as a pharmaceutical composition comprising a therapeutically effective amount of the compound of the present invention or its pharma- ceutically acceptable salt, and a pharma- ceutical acceptable carrier, and may include conventional excipients. A therapeutically effective amount is an amount necessary to obtain a significant improvement in a patient. A pharma- ceutical acceptable carrier is a conventionally known carrier with an acceptable safety profile. The composition encompasses all common solid and liquid forms, such as capsules, tablets, lozenges, and powders, as well as liquid suspensions, syrups, elixirs, and solutions. The composition is prepared using conventional formulation techniques, and conventional excipients (such as binding agents and wetting agents) and vehicles (such as water and alcohol) are generally used in the composition. See, for example, Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, PA (1985).
[0052] Solid compositions are preferably formulated in dosage units and compositions usually having about 1-1000 mg of active ingredient per dosage. Some examples of dosage amounts are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000 mg. In general, other antiretroviral drugs are present in a unit range similar to that of the clinically used type of drug, which is generally 0.25-1000 mg / unit.
[0053] Liquid compositions are usually present in unit dosage ranges. Generally, liquid compositions can be in the dosage unit range of 1-100 mg / mL. Some examples of dosage amounts include 1 mg / mL, 10 mg / mL, 25 mg / mL, 50 mg / mL, and 100 mg / mL.
[0054] The present invention encompasses all conventional methods of administration, although oral and parenteral methods are preferred. In general, the dosage regimen is similar to other drugs used clinically. In general, the daily dose is 1-100 mg / kg (body weight). In general, more oral and less parenteral compounds are desired. However, the specific dosage regimen is determined by the physician according to ordinary medical judgment.
[0055] (Chemical Methods) It will be apparent to those skilled in the art that the present disclosure is not limited to the above-described examples, and that it may be embodied in other specific forms without departing from the essential characteristics of the present disclosure. The examples are therefore to be considered in all respects as illustrative and not restrictive, with reference to the claims rather than to the above-described examples, and therefore all changes which come within the meaning and range of equivalency of the claims are intended to be embraced.
[0056] Section A LCMS analyses were performed using a Waters Acquity UPLC system equipped with a Waters TUV and SQ mass spectrometer (column: BEH C18 2.1 x 50 mm; mobile phase A: water containing 0.05% TFA; mobile phase B: acetonitrile containing 0.05% TFA; gradient: 2-98% B over 1.6 min; flow rate: 0.8 mL / min). HPLC analysis was performed using a Shimadzu LC10-AT HPLC system equipped with an SPD-10AV UV detector (column YMC S5 Combiscreen ODS 4.6 x 50 mm; mobile phase A: 5:95 acetonitrile:water (containing 0.1% TFA); mobile phase B: 95:5 acetonitrile:water (containing 0.1% TFA); gradient: 0-100% B over 40 min, followed by 100% B for 1 min; flow rate: 1 mL / min). Preparative HPLC purification was performed using a Shimadzu LC-8 preparative HPLC system equipped with an SPD 20 UV detector, the detailed conditions are described in the Experimental Methods.
[0057] (Manufacturing method) Example 1 (representative of Method A) (2R,3R,4S,5R,6R)-5-Hydroxy-6-(hydroxymethyl)-3-methoxy-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide [ka]
[0058] Step 1. Methyl (2S,4aR,6R,7R,8S,8aR)-7-acetoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate To a solution of methyl (4aR,6R,7R,8S,8aR)-7-acetoxy-8-azido-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate (2.30 g, 6.10 mmol) in DMF (20.73 mL) and water (4.15 mL) was added sodium ascorbate (1.207 g, 6.10 mmol), copper(II) sulfate pentahydrate (1.370 g, 5.49 mmol), and 5-ethynyl-1,2,3-trifluorobenzene (1.713 g, 10.97 mmol). The reaction mixture was degassed and then heated at 85° C. for 1.5 h. The resulting reaction mixture was poured onto ice and filtered. The filter cake was washed with water (50 mL) and DCM (30 mL) and dried under vacuum to give methyl (4aR,6R,7R,8S,8aR)-7-acetoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate (3.4 g, 6.05 mmol, 99% yield) as a pale yellow solid. LCMS (M+H) + =534.0; 1 H NMR (500MHz, DMSO-d6) δ 8.83 (br s, 1H), 7.83 (br s, 2H), 7.46-7.31 (m, 5H), 5.69 (br s, 2H), 5.65-5.57 (m, 1H), 4.59 (br s, 1H), 4.53-4.45 (m, 1H), 4.17 (br d, J=14.0Hz, 2H), 4.03 (br s, 1H), 3.66 (br s, 3H), 1.84 (br s, 3H)
[0059] Step 2. (2S,4aR,6R,7R,8R,8aR)-7-Hydroxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid To a solution of methyl (4aR,6R,7R,8S,8aR)-7-acetoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate (356 mg, 0.667 mmol) in THF (20 mL) was added a solution of lithium hydroxide (80 mg, 3.34 mmol) in water (4 mL) over 2 min at room temperature. The mixture was stirred at room temperature for 2.5 h. The reaction was complete and homogeneous. The reaction mixture was concentrated to dryness under reduced pressure. Water (4 mL) was added to the residue, and the resulting mixture was acidified to pH 3-4 with HCl (1N). The insoluble product, (4aR,6R,7R,8R,8aR)-7-hydroxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid (0.320 g, 0.670 mmol, 100% yield), was collected by suction filtration as a beige solid and dried under vacuum with Drylite. LCMS (M+H) + =478.0
[0060] Step 3. (2S,4aR,6R,7R,8R,8aR)-7-Hydroxy-N-(2-methylbenzo[d]thiazol-6-yl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide A mixture of (4aR,6R,7R,8R,8aR)-7-hydroxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid (200 mg, 0.419 mmol), 2-methylbenzo[d]thiazol-6-amine (55 mg, 0.335 mmol), benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP) (296 mg, 0.670 mmol), and N,N-diisopropylethylamine (0.190 mL, 1.089 mmol) was stirred in DMF (3.5 mL) at room temperature for 16 hours. To this mixture, water (10 mL) was added and the precipitated material was collected by suction filtration. The filter cake was further purified by flash chromatography (40 g silica gel, dusted column, 1-10% methanol / dichloromethane) to give (4aR,6R,7R,8R,8aR)-7-hydroxy-N-(2-methylbenzo[d]thiazol-6-yl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (96 mg, 0.154 mmol, 36.7% yield) as a beige solid. LCMS (M+H) + =624.1
[0061] Step 4. (2S,4aR,6R,7R,8R,8aR)-7-Methoxy-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide To a solution of (4aR,6R,7R,8R,8aR)-7-hydroxy-N-(2-methylbenzo[d]thiazol-6-yl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (19 mg, 0.030 mmol) and iodomethane (2N, t-butyl ethyl ether, 0.061 mL, 0.122 mmol) was added sodium hydride (60% dispersion in oil, 4.87 mg, 0.122 mmol) in one portion at 0° C. The mixture was stirred at room temperature for 30 min and then quenched with AcOH (0.5 mL). The mixture was diluted with acetic acid (0.5 mL) and injected into a preparative HPLC. The collected fractions were concentrated under reduced pressure, basified with saturated NaHCO3 solution, and extracted with dichloromethane (3 x 20 mL). The combined extracts were dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to give the desired product, (4aR,6R,7R,8R,8aR)-7-methoxy-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (9 mg, 0.014 mmol, 45.3% yield) as a white solid. 1 H NMR (600MHz, chloroform-d) δ 8.08 (s, 1H), 8.00 (d, J=8.5Hz, 1H), 7.83 (br s, 1H), 7.48-7.37 (m, 8H), 5.44 (s, 1H), 4.80 (dd, J=10.6, 3.4Hz, 1H), 4.42 (dd, J=10.6, 8.9Hz, 1H), 4.29 (dd, J=12.6, 1.2Hz, 1H), 4.22 (d, J=2.8Hz, 1H), 3.95 (dd, J=12.5, 1.7Hz, 1H), 3.79 (d, J=8.9Hz, 1H), 3.40 (s, 3H), 3.11 (br s, 1H), 3.08 (s, 3H), 2.90 (s, 3H)
[0062] Step 5. (2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide A solution of (4aR,6R,7R,8R,8aR)-7-methoxy-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (9 mg, 0.014 mmol) in 70% aqueous acetic acid (1 mL) was heated at 70 °C for 4 h. The mixture was diluted with methanol (1 mL) and injected onto a preparative HPLC (Column: Phenomenex Luna AXIA 5u C18 21.2 x 100; Solvent A: 90% H2O-10% MeOH-0.1% TFA, Solvent B: 10% MeOH-90% H2O-0.1% TFA; Start: 25% B, End: 100% B). The collected fractions were concentrated under reduced pressure, basified with saturated NaHCO3 solution, and extracted with dichloromethane (3 x 25 mL). The combined extracts were dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to give the desired product, (2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide (6.0 mg, 10.65 μmol, 77% yield) as a white solid. LCMS (M+H) + =564.0; 1H NMR (500MHz, methanol-d4) δ 8.69 (s, 1H), 8.10 (d, J=1.4Hz, 1H), 8.00 (d, J=8.5Hz, 1H), 7.68 (dd, J=8.8, 6.6Hz, 2H), 7.56 (dd, J=8.5, 2.2Hz, 1H), 4.69 (dd, J=10.7, 3.0Hz, 1H), 4.50 (dd, J=10.7, 9.1Hz, 1H), 3.93 (d, J=2.5Hz, 1H), 3.81 (d, J=8.8Hz, 1H), 3.77 (dd, J=11.7, 7.3Hz, 1H), 3.64 (dd, J=11.7, hGal-3(HTRF) IC 50 =0.087μM
[0063] Example 2 (representative of Method B) (2R,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide [ka]
[0064] Step 1. (2S,4aR,6R,7R,8S,8aR)-6-((2-methylbenzo[d]thiazol-6-yl)carbamoyl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate To a solution of (4aR,6R,7R,8R,8aR)-7-hydroxy-N-(2-methylbenzo[d]thiazol-6-yl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (70 mg, 0.112 mmol) in dichloromethane (5 mL) was added acetyl chloride (0.016 mL, 0.225 mmol) followed by pyridine (0.023 mL, 0.281 mmol) at 0° C. The mixture was stirred at room temperature for 30 min, diluted with ethyl acetate (60 mL) and washed with water (15 mL), saturated NaHCO3 solution (15 mL), and brine (15 mL). The organic layer was dried over MgSO4. The solvent was removed under reduced pressure to give the desired product, (4aR,6R,7R,8S,8aR)-6-((2-methylbenzo[d]thiazol-6-yl)carbamoyl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate (75 mg, 0.113 mmol, 100% yield) as a beige solid. LCMS (M+H) + =666.1
[0065] Step 2. (2S,4aR,6R,7R,8S,8aR)-6-(methyl(2-methylbenzo[d]thiazol-6-yl)carbamoyl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate To a solution of (4aR,6R,7R,8S,8aR)-6-((2-methylbenzo[d]thiazol-6-yl)carbamoyl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate (75 mg, 0.113 mmol) and iodomethane (2N, t-butyl ethyl ether, 0.085 mL, 0.169 mmol) was added sodium hydride (60% dispersion in oil, 9.01 mg, 0.225 mmol) in one portion at 0° C. The mixture was stirred at room temperature for 30 min and then quenched with AcOH (0.5 mL). The mixture was diluted with ethyl acetate (50 mL), washed with water (2 x 15 mL) and brine (15 mL), and dried over anhydrous Na2SO4. The desired product, (4aR,6R,7R,8S,8aR)-6-(methyl(2-methylbenzo[d]thiazol-6-yl)carbamoyl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate (50 mg, 0.074 mmol, 65.3% yield), was isolated by flash chromatography (24 g silica gel, dusted column, 80-100% ethyl acetate / hexanes) as a white solid. LCMS (M+H) + =680.1
[0066] Step 3. (2S,4aR,6R,7R,8R,8aR)-7-Hydroxy-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide To a solution of (4aR,6R,7R,8S,8aR)-6-(methyl(2-methylbenzo[d]thiazol-6-yl)carbamoyl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate (50 mg, 0.074 mmol) in THF (2.5 mL) was added a solution of lithium hydroxide (8.81 mg, 0.368 mmol) in water (0.5 mL) over 2 min at room temperature. The mixture was stirred at room temperature for 2 h and then concentrated to dryness under reduced pressure. Water (20 mL) was added to the residue and the resulting mixture was acidified to pH 3-4 with HCl (2N). The insoluble product, (4aR,6R,7R,8R,8aR)-7-hydroxy-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (43 mg, 0.067 mmol, 92% yield), was collected by suction filtration as a beige solid and dried under vacuum at 50° C. LCMS (M+H) + =638.0
[0067] Step 4. (2R,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide A solution of (4aR,6R,7R,8R,8aR)-7-hydroxy-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (43 mg, 0.067 mmol) in 70% aqueous acetic acid (2 mL) was heated at 70 °C for 5 h. The mixture was diluted with methanol and injected onto a preparative HPLC (Column: Phenomenex Luna AXIA 5u C18 21.2 x 100; Solvent A: 90% H2O-10% MeOH-0.1% TFA, Solvent B: 10% MeOH-90% H2O-0.1% TFA; Start: 20% B, End: 100% B). The collected fractions were concentrated under reduced pressure, basified with saturated NaHCO3 solution, and extracted with dichloromethane (3 x 25 mL). The combined extracts were dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to give the desired product, (2R,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-N-methyl-N-(2-methylbenzo[d]thiazol-6-yl)-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide (20 mg, 0.036 mmol, 54.0% yield) as a white solid. LCMS (M+H) + =550.0; 1H NMR (500MHz, methanol-d4) δ 8.54 (s, 1H), 8.10 (d, J=1.7Hz, 1H), 8.00 (d, J=8.5Hz, 1H), 7.65 (dd, J=8.7, 6.7Hz, 2H), 7.57 (dd, J=8.5, 2.2Hz, 1H), 4.76 (dd, J=11.0, 9.1Hz, 1H), 4.64 (dd, J=11.0, 3.0Hz, 1H), 3.97 (d, J=2.5Hz, 1H), 3.84 (d, J=9.1Hz, 1H), 3.75 (dd, J=11.6, 7.2Hz, 1H), 3.68-3.61 (m, 1H), 3.42 (s, 3H), 3.38-3.34 (m, 1H), 2.89 (s, 3H); hGal-3(HTRF) IC 50 =0.109μM
[0068] Example 3 (representative of Method C) (2R,3R,4S,5R,6R)-N-(6-chloroquinolin-8-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-N-methyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide [ka]
[0069] Step 1. Methyl (2S,4aR,6R,7R,8R,8aR)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate To a solution of (4aR,6R,7R,8R,8aR)-7-hydroxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid (670 mg, 1.403 mmol) and iodomethane (0.349 mL, 5.61 mmol) in DMF (12 mL) was added sodium hydride (60% dispersion in oil, 281 mg, 7.02 mmol) in one portion at 0° C. The mixture was stirred at room temperature for 6 h and then at 50° C. for 10 h. After cooling again to 0° C., additional iodomethane (0.175 mL, 2.80 mmol) and sodium hydride (60% dispersion in oil, 140 mg, 2.31 mmol) were added. The mixture was heated at 50° C. for an additional 4 h. It was cooled to 0° C., quenched with acetic acid (1 mL, 17.47 mmol), diluted with water (150 mL) and adjusted to pH 7. The insoluble material was collected by suction filtration and subsequently purified by flash chromatography (80 g silica gel, dusted column, 30-65% ethyl acetate / hexanes) to give the desired product, methyl (4aR,6R,7R,8R,8aR)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate (236 mg, 0.467 mmol, 33.3% yield) as a white solid. LCMS (M+H) + =506.0
[0070] Step 2. (2S,4aR,6R,7R,8R,8aR)-7-Methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid To a solution of methyl (4aR,6R,7R,8R,8aR)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate (234 mg, 0.463 mmol) in THF (10 mL) was added a solution of lithium hydroxide (55.4 mg, 2.315 mmol) in water (2 mL) over 2 min at room temperature. The mixture was stirred at room temperature for 2 h and then concentrated to dryness under reduced pressure. Water (10 mL) was added to the residue and the resulting mixture was acidified to pH 4-5 with HCl (1N). The insoluble product, (4aR,6R,7R,8R,8aR)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid (221 mg, 0.450 mmol, 97% yield) was collected by suction filtration as a white solid and dried under vacuum at 50° C. LCMS (M+H) + =492.0
[0071] Step 3. (2S,4aR,6R,7R,8R,8aR)-N-(6-chloroquinolin-8-yl)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide A mixture of (4aR,6R,7R,8R,8aR)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid (25 mg, 0.051 mmol), 6-chloroquinolin-8-amine (18.17 mg, 0.102 mmol), benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP) (36.0 mg, 0.081 mmol), and N,N-diisopropylethylamine (0.036 mL, 0.203 mmol) in DMF (0.5 mL) was stirred at room temperature for 7 hours. The mixture was diluted with methanol and injected onto a preparative HPLC (Column: Phenomenex Luna AXIA 5u C18 21.2 x 100; Solvent A: 90% H2O-10% MeOH-0.1% TFA, Solvent B: 10% MeOH-90% H2O-0.1% TFA; Start: 44% B, End: 100% B). The collected fractions were combined, concentrated in vacuo, basified with saturated NaHCO3 solution, and extracted with dichloromethane (3 x 25 mL). The combined extracts were dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to give the desired product, (4aR,6R,7R,8R,8aR)-N-(6-chloroquinolin-8-yl)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (12 mg, 0.018 mmol, 36.2% yield) as a beige solid. LCMS (M+H) + =652.0
[0072] Step 4. (2S,4aR,6R,7R,8R,8aR)-N-(6-chloroquinolin-8-yl)-7-methoxy-N-methyl-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide To a solution of (4aR,6R,7R,8R,8aR)-N-(6-chloroquinolin-8-yl)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (12 mg, 0.018 mmol) and iodomethane (2N, t-butyl ethyl ether, 0.023 mL, 0.046 mmol) was added sodium hydride (60% dispersion in oil, 1.840 mg, 0.046 mmol) in one portion at 0° C. The mixture was stirred at room temperature for 30 min and then quenched with AcOH (0.5 mL). The mixture was diluted with ethyl acetate (50 mL) and washed with saturated NaHCO3 solution (15 mL), water (2 x 15 mL), and brine (15 mL). The organic layer was dried over anhydrous MgSO4 and concentrated in vacuo to give (4aR,6R,7R,8R,8aR)-N-(6-chloroquinolin-8-yl)-7-methoxy-N-methyl-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (12 mg, 0.018 mmol, 98% yield) as a beige solid. LCMS (M+H) + =666.1
[0073] Step 5. (2R,3R,4S,5R,6R)-N-(6-chloroquinolin-8-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-N-methyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide A solution of (4aR,6R,7R,8R,8aR)-N-(6-chloroquinolin-8-yl)-7-methoxy-N-methyl-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (12 mg, 0.018 mmol) in 70% acetic acid (1 mL) was heated at 70° C. for 6 h. The mixture was diluted with methanol and injected onto a preparative HPLC (column: Phenomenex Luna AXIA 5u C18 21.2 x 100; Solvent A: 90% HO-10% methanol-0.1% TFA, Solvent B: 10% methanol-90% HO-0.1% TFA; starting: 25% B, final: 100% B). The collected fractions were combined, concentrated under reduced pressure, basified with K2HPO4 solution (1N) and extracted with dichloromethane (3 x 25 mL). The combined extracts were dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to give (2R,3R,4S,5R,6R)-N-(6-chloroquinolin-8-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-N-methyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide (4.0 mg, 6.48 μmol, 36.0% yield) as a white solid. LCMS (M+H) + =578.0; 1 H NMR (500MHz, methanol-d4) δ 9.02-8.93 (m, 1H), 8.66 (s, 1H), 8.46-8.36 (m, 1H), 8.14 (br d, J=2.2Hz, 1H), 8.03 (br s, 1H), 7.73-7.61 (m, 3H), 4.61-4.55 (m, 1H), 4.56-4.49 (m, 1H), 3.93 (br s, 1H), 3.82-3.74 (m, 1H), 3.72-3.64 (m, 1H), 3.48 (s, 3H), 3.44-3.39 (m, 1H), 3.30-3.26 (m, 1H), 3.21-3.13 (s, 3H); hGal-3(HTRF) IC 50 =0.057μM
[0074] Example 4 (representative of Method D) (2R,3R,4S,5R,6R)-N-(benzo[d]thiazol-6-yl)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-N-methyltetrahydro-2H-pyran-2-carboxamide [ka]
[0075] Step 1. ((4-chloro-3,5-difluorophenyl)ethynyl)trimethylsilane To a degassed mixture of 5-bromo-2-chloro-1,3-difluorobenzene (27.3 g, 120 mmol), copper(I) iodide (0.389 g, 2.041 mmol) and bis(triphenylphosphine)palladium(II) chloride (1.432 g, 2.041 mmol) in triethylamine (120 mL) was added ethynyltrimethylsilane (17.30 mL, 122 mmol) dropwise at room temperature under nitrogen over 20 minutes. The mixture was stirred at room temperature until the reaction was complete (monitored by HPLC). It was diluted with hexane (100 mL) and the insoluble material was removed by filtration. The filtrate was concentrated under reduced pressure and the resulting residue was loaded onto a 220 g silica gel flash column (solvent: hexanes) to give ((4-chloro-3,5-difluorophenyl)ethynyl)trimethylsilane (29.23 g, 109 mmol, 91% yield) as an oil. 1 H NMR (400 MHz, chloroform-d) δ 7.03-7.10 (m, 2H), 0.22-0.29 (m, 9H)
[0076] Step 2. Methyl (4aR,6R,7R,8S,8aR)-7-acetoxy-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate To a solution of methyl (4aR,6R,7R,8S,8aR)-7-acetoxy-8-azido-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate (0.200 g, 0.530 mmol) in DMF (3.79 mL) and water (1.514 mL) was added (+)-sodium ascorbate (0.105 g, 0.530 mmol), copper(II) sulfate pentahydrate (0.119 g, 0.477 mmol), and ((4-chloro-3,5-difluorophenyl)ethynyl)trimethylsilane (0.259 g, 1.060 mmol). The reaction mixture was degassed and heated at 85° C. for 1.5 hours. The reaction was poured onto ice. The resulting insoluble material was collected by suction filtration and dried in vacuum. The crude product was further purified by flash chromatography (24 g silica gel, dust column, 0-50% ethyl acetate / dichloromethane) to give methyl (4aR,6R,7R,8S,8aR)-7-acetoxy-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate (286 mg, 0.520 mmol, 98% yield) as a white solid. LCMS (M+H) + =550.1; 1 H NMR (400MHz, chloroform-d) δ 8.08 (s, 1H), 7.42-7.46 (m, 5H), 7.39-7.41 (m, 1H), 7.37-7.39 (m, 1H), 5.88 (dd, J=9.46, 11.00Hz, 1H), 5.52 (s, 1H), 5.20 (dd, J=3.41, 10.89Hz, 1H), 4.45-4.51 (m, 2H), 4.23 (d, J=9.68Hz, 1H), 4.09-4.16 (m, 1H), 3.81 (s, 3H), 3.79 (d, J=1.10Hz, 1H), 1.88 (s, 3H)
[0077] Step 3. (4aR,6R,7R,8R,8aR)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid To a solution of methyl (4aR,6R,7R,8S,8aR)-7-acetoxy-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate (286 mg, 0.520 mmol) in THF (11.0 mL) was added LiOH (1N aq., 2.60 mL, 2.60 mmol). The reaction mixture was stirred at room temperature for 30 min, diluted with water (10 mL), acidified to pH 5 with aq. HCl (1N), and extracted with ethyl acetate (2 x 20 mL). The combined extracts were dried over MgSO4, filtered, and concentrated in vacuo to give (4aR,6R,7R,8R,8aR)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid (241 mg, 0.488 mmol, 94% yield) as a white solid. LCMS (M+H) + = 494.1; 1 H NMR (400MHz, DMSO-d6) δ 8.93 (s, 1H), 7.84 (d, J=8.36Hz, 2H), 7.29-7.36 (m, 5H), 5.52 (s, 1H), 5.10 (td, J=3.52, 6.60Hz, 1H), 4.43 (br s, 2H), 4.04-4.21 (m, 2H), 3.87 (br s, 2H)
[0078] Step 4. (4aR,6R,7R,8R,8aR)-N-(benzo[d]thiazol-6-yl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide To (4aR,6R,7R,8R,8aR)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid (108 mg, 0.219 mmol) and benzo[d]thiazol-6-amine·2HCl (53.7 mg, 0.241 mmol) in dichloromethane (5 mL) was added N,N-diisopropylethylamine (0.153 mL, 0.875 mmol) followed by 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (50% in EtOAc, 557 mg, 0.875 mmol). The resulting solution was stirred at room temperature for 1 h and then concentrated under reduced pressure. The residue was purified by flash chromatography (80 g silica gel, dust column, 0-90% ethyl acetate / hexanes) to give (4aR,6R,7R,8R,8aR)-N-(benzo[d]thiazol-6-yl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (106 mg, 0.169 mmol, 77% yield) as a white solid. LCMS (M+H) + =626.2; 1 H NMR (400MHz, chloroform-d) δ 8.98 (s, 1H), 8.76 (s, 1H), 8.54 (d, J=2.20Hz, 1H), 8.12 (d, J=8.80Hz, 1H), 8.06-8.08 (m, 1H), 7.50 (dd, J=1.98, 8.80Hz, 1H), 7.41-7.46 (m, 2H), 7.38 (s, 4H), 5.55 (s, 1H), 5.14 (dd, J=3.08, 10.56Hz, 1H), 4.98 (br s, 1H), 4.69 (t, J=10.01Hz, 1H), 4.63 (d, J=2.64Hz, 1H), 4.56 (dd, J=1.21, 12.87Hz, 1H), 4.23 (d, J=9.46Hz, 2H), 3.95 (s, 1H)
[0079] Step 5. (4aR,6R,7R,8R,8aR)-N-(benzo[d]thiazol-6-yl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-methoxy-N-methyl-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide To (4aR,6R,7R,8R,8aR)-N-(benzo[d]thiazol-6-yl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (25 mg, 0.040 mmol) in DMF (1.0 mL) was added sodium hydride (60% dispersion in oil, 7.99 mg, 0.200 mmol) followed by iodomethane (0.012 mL, 0.200 mmol). The resulting mixture was stirred at room temperature for 30 min, quenched with water (10 mL) and extracted with ethyl acetate (20 mL). The organic solution was dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (12 g silica gel, 0-90% ethyl acetate / hexanes) to give (4aR,6R,7R,8R,8aR)-N-(benzo[d]thiazol-6-yl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-methoxy-N-methyl-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (22 mg, 0.034 mmol, 84% yield) as a beige solid. LCMS (M+H) + = 654.2; 1H NMR (400MHz, chloroform-d) δ 8.21 (d, J=8.58Hz, 1H), 8.13 (s, 1H), 7.96-8.06 (m, 2H), 7.54 (dd, J=1.98, 8.58Hz, 1H), 7.38-7.48 (m, 7H), 5.44 (s, 1H), 4.81 (dd, J=3.30, 10.56Hz, 1H), 4.43 (dd, J=9.02, 10.56Hz, 1H), 4.30 (dd, J=1.21, 12.65Hz, 1H), 4.19-4.25 (m, 1H), 3.95 (dd, J=1.54, 12.76Hz, 1H), 3.80 (d, J=9.02Hz, 1H), 3.42 (s, 3H), 3.12 (s, 1H), 3.08 (s, 3H)
[0080] Step 6. (2R,3R,4S,5R,6R)-N-(benzo[d]thiazol-6-yl)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-N-methyltetrahydro-2H-pyran-2-carboxamide A mixture of (4aR,6R,7R,8R,8aR)-N-(benzo[d]thiazol-6-yl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-methoxy-N-methyl-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (22 mg, 0.034 mmol) in acetic acid (0.7 mL) and water (0.3 mL) was heated at 65° C. overnight. The resulting reaction mixture was diluted with methanol and injected onto a preparative HPLC (column: Phenomenex Luna AXIA 5u 30 x 100; Solvent A: 90% H2O-10% ACN-0.1% TFA, Solvent B: 90% ACN-10% H2O-0.1% TFA; Start: 25% B, End: 80% B). The collected fractions were combined, concentrated under reduced pressure, basified with saturated NaHCO3 solution, and extracted with dichloromethane (2 x 25 mL). The solvent was removed under reduced pressure to give the desired product, (2R,3R,4S,5R,6R)-N-(benzo[d]thiazol-6-yl)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-N-methyltetrahydro-2H-pyran-2-carboxamide (11 mg, 0.019 mmol, 56.6% yield) as a white solid. LCMS (M+H) + =566.1; 1 H NMR (400MHz, methanol-d4) δ 9.35 (s, 1H), 8.73 (s, 1H), 8.22-8.27 (m, 1H), 8.12-8.22 (m, 1H), 7.64-7.70 (m, 2H), 7.58-7.64 (m, 1H), 4.69 (dd, J=2.86, 10.78Hz, 1H), 4.50 (dd, J=9.13, 10.67Hz, 1H), 3.91 (d, J=2.42Hz, 1H), 3.78-3.83 (m, 1H), 3.73-3.78 (m, 1H), 3.63 (dd, J=4.51, 11.77Hz, 1H), 3.43 (s, 3H), 3.34 (br s, 1H), 3.14 (s, 3H); hGal-3(HTRF) IC 50=0.033μM
[0081] Example 5 (representative of Method E) (2R,3R,4S,5R,6R)-N-(5-chloro-2-(trifluoromethyl)phenyl)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)-N-methyltetrahydro-2H-pyran-2-carboxamide [ka]
[0082] Step 1. (4aR,6R,7R,8S,8aR)-7-acetoxy-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid To a suspension of methyl (4aR,6R,7R,8S,8aR)-7-acetoxy-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylate (1.1 g, 2.000 mmol) in THF (45.5 mL) and methanol (4.55 mL) was added aqueous lithium hydroxide (1N, 2.000 mL, 2.000 mmol) dropwise. The reaction mixture was stirred at room temperature overnight, diluted with water (30 mL), acidified to pH 3-4 with aqueous HCl (1 M), and extracted with EtOAc (2 x 50 mL). The combined extracts were dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (80 g silica gel, dust column, 0-15% methanol / dichloromethane) to give (4aR,6R,7R,8S,8aR)-7-acetoxy-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid (215 mg, 0.401 mmol, 20% yield) as a white solid. LCMS (M+H)+ =536.2; 1 H NMR (400MHz, methanol-d4) δ 8.33 (s, 1H), 7.42-7.49 (m, 4H), 7.36-7.40 (m, 3H), 5.84 (t, J=10.23Hz, 1H), 5.58 (s, 1H), 5.40 (dd, J=2.97, 10.89Hz, 1H), 4.56 (d, J=3.08Hz, 1H), 4.39 (d, J=12.76Hz, 1H), 4.31 (d, J=9.68Hz, 1H), 4.17 (d, J=12.76Hz, 1H), 3.92 (s, 1H), 1.85 (s, 3H)
[0083] Step 2. (4aR,6R,7R,8S,8aR)-6-((5-chloro-2-(trifluoromethyl)phenyl)carbamoyl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate To (4aR,6R,7R,8S,8aR)-7-acetoxy-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid (66 mg, 0.123 mmol) and 5-chloro-2-(trifluoromethyl)aniline (27.7 mg, 0.142 mmol) in DCE (1.0 mL) was added pyridine (0.040 mL, 0.493 mmol) followed by 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (50% in EtOAc, 314 mg, 0.493 mmol). The resulting solution was stirred at 80 °C for 2 h. The mixture was concentrated under reduced pressure and the resulting residue was purified by flash chromatography (12 g silica gel, 0-5% methanol / dichloromethane) to give (4aR,6R,7R,8S,8aR)-6-((5-chloro-2-(trifluoromethyl)phenyl)carbamoyl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate (70 mg, 0.098 mmol, 80% yield) as a film. LCMS (M+H) + =713.3; 1 H NMR (400MHz, chloroform-d) δ 9.06 (br s, 1H), 8.29 (d, J=1.32Hz, 1H), 7.96 (s, 1H), 7.57 (d, J=8.58Hz, 1H), 7.41-7.45 (m, 5H), 7.37 (d, J=7.48Hz, 2H), 7.24 (dd, J=1.10, 8.36Hz, 1H), 5.83 (dd, J=9.68, 11.00Hz, 1H), 5.54 (s, 1H), 5.28-5.34 (m, 1H), 4.55 (d, J=3.08Hz, 1H), 4.49 (dd, J=1.43, 12.87Hz, 1H), 4.28 (d, J=9.68Hz, 1H), 4.18 (dd, J=1.54, 12.98Hz, 1H), 3.94 (d, J=0.66Hz, 1H), 1.98 (s, 3H)
[0084] Step 3. (4aR,6R,7R,8R,8aR)-N-(5-chloro-2-(trifluoromethyl)phenyl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-N-methyl-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide To (4aR,6R,7R,8S,8aR)-6-((5-chloro-2-(trifluoromethyl)phenyl)carbamoyl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl acetate (35 mg, 0.037 mmol) and K2CO3 (25.4 mg, 0.184 mmol) in DMF (1.0 mL) was added iodomethane (6.87 μL, 0.110 mmol). The mixture was stirred at 90 °C for 1 h and concentrated under reduced pressure to remove volatiles. To the remaining solution was added aqueous lithium hydroxide (1N, 0.110 mL, 0.110 mmol) and the mixture was stirred at room temperature for 30 min. The mixture was concentrated to dryness in vacuo and the resulting residue was purified by flash chromatography (12 g silica gel, 0-4% methanol / dichloromethane) to give (4aR,6R,7R,8R,8aR)-N-(5-chloro-2-(trifluoromethyl)phenyl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-N-methyl-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (19 mg, 0.028 mmol, 75% yield) as a film. LCMS (M+H) + =685.3
[0085] Step 4. (2R,3R,4S,5R,6R)-N-(5-chloro-2-(trifluoromethyl)phenyl)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)-N-methyltetrahydro-2H-pyran-2-carboxamide A mixture of (4aR,6R,7R,8R,8aR)-N-(5-chloro-2-(trifluoromethyl)phenyl)-8-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-7-hydroxy-N-methyl-2-phenylhexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (19 mg, 0.028 mmol) in acetic acid (0.7 mL) and water (0.3 mL) was stirred at 90° C. for 2 hours. The mixture was diluted with methanol and injected onto a preparative HPLC (Column: Phenomenex Luna AXIA 30 x 100mm C18 5u; Solvent A: 90%H2O-10%ACN-0.1%TFA, Solvent B: 90%ACN-10%H2O-0.1%TFA; Start: 30%B, End: 70%B). The collected fractions were combined, concentrated in vacuo, basified with saturated NaHCO3 solution and extracted with dichloromethane (2 x 25mL). The solvent was removed under reduced pressure to give the desired product, (2R,3R,4S,5R,6R)-N-(5-chloro-2-(trifluoromethyl)phenyl)-4-(4-(4-chloro-3,5-difluorophenyl)-1H-1,2,3-triazol-1-yl)-3,5-dihydroxy-6-(hydroxymethyl)-N-methyltetrahydro-2H-pyran-2-carboxamide (5 mg, 7.95 μmol, 28.7% yield) as an off-white solid. LCMS (M+H) + =597.2; 1H NMR (400MHz, methanol-d4) δ 8.57 (d, J=5.06Hz, 1H), 7.86 (d, J=8.58Hz, 1H), 7.79 (d, J=1.76Hz, 1H), 7.68-7.74 (m, 1H), 7.65 (d, J=7.92Hz, 2H), 7.56 (d, J=1.54Hz, 1H), 4.68 (dd, J=2.75, 11.33Hz, 1H), 4.47-4.65 (m, 1H), 4.01 (d, J=2.86Hz, 1H), 3.80 (d, J=8.80Hz, 1H), 3.66-3.72 (m, 1H), 3.60-3.65 (m, 1H), 3.50-3.53 (m, 1H), 3.27 (d, J=5.28Hz, 3H); hGal-3(HTRF) IC 50 =0.051μM
[0086] Example 6 (Representative of Method F) (2R,3R,4S,5R,6R)-N-(benzo[b]thiophen-6-yl)-3,5-dihydroxy-6-(hydroxymethyl)-N-methyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide [ka]
[0087] Step 1. (4aR,6R,7R,8R,8aR)-N-(benzo[b]thiophen-6-yl)-7-hydroxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide To (4aR,6R,7R,8R,8aR)-7-hydroxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid (100 mg, 0.209 mmol) and benzo[b]thiophene-6-amine (34.4 mg, 0.230 mmol) in DCM (3.0 mL) was added N,N-diisopropylethylamine (0.146 mL, 0.838 mmol) followed by 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (50% in EtOAc, 533 mg, 0.838 mmol). The solution was stirred at room temperature for 1 h and concentrated under reduced pressure. The resulting residue was purified by flash chromatography (12 g silica gel, 0-3% methanol / dichloromethane) to give (4aR,6R,7R,8R,8aR)-N-(benzo[b]thiophen-6-yl)-7-hydroxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (111 mg, 0.182 mmol, 87% yield) as an off-white solid. LCMS (M+H) + =609.2; 1 H NMR (400MHz, chloroform-d) δ 8.66 (s, 1H), 8.36 (d, J=1.98Hz, 1H), 8.03 (s, 1H), 7.81 (d, J=8.36Hz, 1H), 7.40-7.46 (m, 4H), 7.38-7.39 (m, 4H), 7.32 (dd, J=0.66, 5.28Hz, 1H), 5.54 (s, 1H), 5.09-5.17 (m, 1H), 5.05-5.09 (m, 1H), 4.65-4.74 (m, 1H), 4.51-4.63 (m, 2H), 4.22-4.25 (m, 1H), 4.17-4.22 (m, 1H), 3.90-3.96 (m, 1H)
[0088] Step 2. (2R,3R,4S,5R,6R)-N-(benzo[b]thiophen-6-yl)-3,5-dihydroxy-6-(hydroxymethyl)-N-methyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide In a sealed tube, (4aR,6R,7R,8R,8aR)-N-(benzo[b]thiophen-6-yl)-7-hydroxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (55 mg, 0.090 mmol) and K2CO3 (62.4 mg, 0.452 mmol) in DMF (2.0 mL) were added iodomethane (38.5 mg, 0.271 mmol). The mixture was stirred at 60° C. for 1 day and then at 90° C. for 2 days. The mixture was diluted with methanol and injected onto a preparative HPLC (Column: Phenomenex Luna AXIA 30 x 100mm C18 5u; Solvent A: 90%H2O-10%ACN-0.1%TFA, Solvent B: 90%ACN-10%H2O-0.1%TFA; Start: 30%B, End: 60%B). The combined collected fractions were concentrated in vacuo, basified with saturated NaHCO3 solution and extracted with dichloromethane (2 x 25mL). The solvent was removed under reduced pressure to give the desired product, (2R,3R,4S,5R,6R)-N-(benzo[b]thiophen-6-yl)-3,5-dihydroxy-6-(hydroxymethyl)-N-methyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide (11 mg, 0.020 mmol, 21.63% yield) as a tan solid. LCMS (M+H) + =535.1; 1H NMR (500MHz, methanol-d4) δ 8.52 (s, 1H), 8.04 (s, 1H), 7.95 (d, J=8.25Hz, 1H), 7.70 (d, J=5.50Hz, 1H), 7.63 (dd, J=6.74, 8.67Hz, 2H), 7.45 (d, J=5.50Hz, 1H), 7.42 (dd, J=1.65, 8.53Hz, 1H), 4.74 (dd, J=9.08, 10.73Hz, 1H), 4.61 (dd, J=2.89, 10.87Hz, 1H), 3.95 (d, J=2.48Hz, 1H), 3.86 (d, J=9.08Hz, 1H), 3.71-3.77 (m, 1H), 3.61-3.66 (m, 1H), 3.40 (s, 3H), 3.33-3.37 (m, 1H)
[0089] Examples 7 and 8 (representative of Method G) (2R,3R,4S,5R,6R)-N-(2-(tert-butyl)-5-chlorophenyl)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-N-methyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide (atropisomers 1 and 2) [ka]
[0090] Step 1. (4aR,6R,7R,8R,8aR)-N-(2-(tert-butyl)-5-chlorophenyl)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide In a sealed tube, a mixture of (4aR,6R,7R,8R,8aR)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxylic acid (30 mg, 0.061 mmol), 2-(tert-butyl)-5-chloroaniline (13.46 mg, 0.073 mmol), pyridine (0.020 mL, 0.244 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (50% in EtOAc, 155 mg, 0.244 mmol) in DCE (1.0 mL) was stirred at 90 °C for 1 h. The mixture was concentrated under reduced pressure and the resulting residue was purified by flash chromatography (12 g silica gel, 0-60% ethyl acetate / hexanes) to give the desired product, (4aR,6R,7R,8R,8aR)-N-(2-(tert-butyl)-5-chlorophenyl)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (39 mg, 0.030 mmol, 48.6% yield) as an off-white solid. LCMS (M+H) + =657.2
[0091] Step 2. (4aR,6R,7R,8R,8aR)-N-(2-(tert-butyl)-5-chlorophenyl)-7-methoxy-N-methyl-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide To (4aR,6R,7R,8R,8aR)-N-(2-(tert-butyl)-5-chlorophenyl)-7-methoxy-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (39 mg, 0.030 mmol) in DMF (1.0 mL) was added sodium hydride (60% dispersion in oil, 5.93 mg, 0.148 mmol) followed by iodomethane (21.06 mg, 0.148 mmol). The mixture was stirred at room temperature for 1 h, diluted with water (20 mL) and extracted with ethyl acetate (40 mL). The organic solution was dried over MgSO4 and concentrated in vacuo. The resulting residue was purified by flash chromatography (12 g silica gel, 0-90% ethyl acetate / hexanes) to give (4aR,6R,7R,8R,8aR)-N-(2-(tert-butyl)-5-chlorophenyl)-7-methoxy-N-methyl-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (30 mg, 0.030 mmol, 99% yield) as an off-white solid. LCMS (M+H) + =671.3
[0092] Step 3. (2R,3R,4S,5R,6R)-N-(2-(tert-butyl)-5-chlorophenyl)-5-hydroxy-6-(hydroxymethyl)-3-methoxy-N-methyl-4-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)tetrahydro-2H-pyran-2-carboxamide (atropisomers 1 and 2) A mixture of (4aR,6R,7R,8R,8aR)-N-(2-(tert-butyl)-5-chlorophenyl)-7-methoxy-N-methyl-2-phenyl-8-(4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl)hexahydropyrano[3,2-d][1,3]dioxine-6-carboxamide (30 mg, 0.030 mmol) in acetic acid (0.7 mL) and water (0.3 mL) was stirred at 60° C. overnight. The mixture was diluted with methanol and injected onto a preparative HPLC (Column: Phenomenex Luna AXIA 30 x 100mm C18 5u; Solvent A: 90%H2O-10%ACN-0.1%TFA, Solvent B: 90%ACN-10%H2O-0.1%TFA; Start: 20%B, End: 60%B). Two products were isolated. The collected fractions for each product were combined, concentrated in vacuo, basified with saturated NaHCO3 solution, and extracted with dichloromethane (2 x 25mL). The solvent was removed in vacuo to give atropisomer 1 (5mg, 8.15μmol, 27.6% yield) and atropisomer 2 (3mg, 4.89μmol, 16.57% yield) as white solids. Atropisomer 1: LCMS (M+H) + =583.2; 1 H NMR (400MHz, methanol-d4) δ 8.63-8.82 (m, 1H), 7.61-7.74 (m, 3H), 7.29-7.46 (m, 1H), 7.03-7.20 (m, 1H), 4.68-4.75 (m, 1H), 4.33-4.45 (m, 1H), 3.98 (d, J=2.64Hz, 1H), 3.85 (d, J=9.24Hz, 1H), 3.63-3.66 (m, 1H), 3.43-3.49 (m, 2H), 3.27 (s, 3H), 3.12-3.17 (m, 3H), 1.35-1.45 (m, 9H); hGal-3(HTRF) IC 50 =0.166μM Atropisomer 2: LCMS (M+H) + =583.2; 1H NMR (400MHz, メタノール-d4) δ 8.72 (s, 1H), 7.66 (d, J=8.80Hz, 3H), 7.43 (dd, J=2.42, 8.80Hz, 1H), 7.35 (d, J=2.42Hz, 1H), 4.70 (dd, J=2.86, 10.78Hz, 1H), 4.52-4.59 (m, 1H), 3.98 (d, J=2.42Hz, 1H), 3.60-3.75 (m, 3H), 3.23 (s, 3H), 3.12-3.17 (m, 1H), 3.09 (s, 3H), 1.38-1.43 (m, 9H); hGal-3(HTRF) IC 50 =0.102μM
Table 2
Table 3
Table 4
Table 5
Table 6
Table 7
Table 8
Table 9
Table 10
Table 11
[0093] Section B General na synthetic スキームB1 Table B1 shows the production of C2-ヒドロキシ derivatives [ka] [Table 12] [Table 13]
[0094] General synthetic scheme B2 Preparation of C2-hydroxy derivatives shown in Table B2 [ka] [Table 14]
[0095] General synthetic scheme B3 Preparation of derivatives shown in Table B3 [ka] [Table 15]
[0096] Example B19 [ka]
[0097] General synthetic scheme B4 Preparation of derivatives shown in Table B4 [ka] [Table 16]
[0098] Example B24 [ka]
[0099] Example B25 [ka] [Claim 1] Formula (I) or (II): [C1] TIFF0007577682000037.tif70153 [In the formula, X is independently -C(O)-, -CH 2 - and -CH 2 C(O)-; Ar 1 is independently phenyl or naphthyl; where each ring is selected from the group consisting of cyano, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, and C 1-4 substituted with 1 to 5 substituents selected from haloalkoxy; R 1 are independently H, C 1-4 Alkyl, and C 1-4 haloalkyl; R 2 are independently H or C 1-4 is alkyl; R 3 are independently 2 , -(CH 2 ) 1-2 Ar 2 , and -CH 2 CH 2 NR 4 Ar 2 Selected from; Ar 2 are independently phenyl, [C2] TIFF0007577682000038.tif1321<h2 style=";text-align:left;direction:ltr"> and 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R <h2 style=";text-align:left;direction:ltr"> 5 <h2 style=";text-align:left;direction:ltr"> ), O, and S; each ring is selected from OH, cyano, halogen, C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Alkyl, C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Haloalkyl, C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Alkoxy, C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Haloalkoxy, N(C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Alkyl) <h2 style=";text-align:left;direction:ltr"> 2<h2 style=";text-align:left;direction:ltr"> , -SO <h2 style=";text-align:left;direction:ltr"> 2<h2 style=";text-align:left;direction:ltr"> (C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Alkyl), -OPh, -OBn, C <h2 style=";text-align:left;direction:ltr"> 3-6 <h2 style=";text-align:left;direction:ltr"> Cycloalkyl; and cyano, halogen, C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Alkyl, C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Haloalkyl, C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Alkoxy, C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Haloalkoxy, -NH <h2 style=";text-align:left;direction:ltr"> 2<h2 style=";text-align:left;direction:ltr"> , -NH(C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> alkyl), and -N(C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Alkyl) <h2 style=";text-align:left;direction:ltr"> 2<h2 style=";text-align:left;direction:ltr"> phenyl substituted by 0-1 substituents selected from; <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> R <h2 style=";text-align:left;direction:ltr"> 4 <h2 style=";text-align:left;direction:ltr"> are independently H or C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> is alkyl; and <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> R <h2 style=";text-align:left;direction:ltr"> 5 <h2 style=";text-align:left;direction:ltr"> are independently H or C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> is alkyl] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> or a pharma- ceutically acceptable salt thereof. <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> [Claim 2] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> The compound has formula (Ia): <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> [C3] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TIFF0007577682000039.tif39153<h2 style=";text-align:left;direction:ltr"> 2. The compound of claim 1, wherein: <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> [Claim 3] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Ar <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> is independently phenyl or naphthyl; wherein each ring is selected from the group consisting of cyano, halogen, C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> Alkyl, and C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> substituted with 1 to 3 substituents selected from alkoxy; <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> R <h2 style=";text-align:left;direction:ltr"> 1 <h2 style=";text-align:left;direction:ltr"> are independently H or C <h2 style=";text-align:left;direction:ltr"> 1-4 <h2 style=";text-align:left;direction:ltr"> is alkyl; and <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Ar <h2 style=";text-align:left;direction:ltr"> 2 are independently phenyl, [C4] TIFF0007577682000040.tif1321 , pyridinyl, benzothiophenyl, benzothiazolyl, N-(C 1-4 each ring is selected from OH, cyano, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, N(C 1-4 Alkyl) 2 , -SO 2 (C 1-4 3. The compound of claim 1 or claim 2, substituted with 0 to 4 substituents selected from -alkyl, -OPh, and -OBn. [Claim 4] Ar 1 But independently, [5] TIFF0007577682000041.tif58153 The compound according to any one of claims 1 to 3, selected from: [Claim 5] R 3 But independently, Ar 2 , -(CH 2 ) 1-2 Ar 2 , and -CH 2 CH 2 NR 4 Ar 2 Selected from; Ar 2 But independently, [6] TIFF0007577682000042.tif108153 The compound according to any one of claims 1 to 4, selected from: [Claim 6] R 1 are independently H or CH 3 and; R 2 However, independently, H, CH 3 , -CH2 CH 3 , and -CH(CH 3 ) 2 Selected from; and R 4 are independently H or CH 3 The compound according to any one of claims 1 to 5, wherein [Claim 7] 2. The compound of claim 1 which is a compound selected from Examples 1-44 and B1-B25, or a pharma- ceutically acceptable salt thereof. [Claim 8] 10. A composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers. [Claim 9] 9. A compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, or a composition according to claim 8, for use as a medicament. [Claim 10] fibrosis of organs (such as liver, kidney, lung, heart and skin), liver diseases and conditions (such as acute hepatitis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, liver regeneration failure, non-alcoholic steatohepatitis (NASH), liver dysfunction and liver blood flow disorder), cell proliferation diseases and cancer diseases (such as solid tumors, solid tumor metastases, angiofibromas, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL) and wet metastasis of cancer cells), inflammatory diseases and conditions (such as psoriasis, nephropathy and pneumonia), gastrointestinal diseases and conditions (such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and abnormal pancreatic secretion), kidney diseases and conditions, urinary tract-related diseases and conditions (benign prostatic hyperplasia or neurogenic bladder-related diseases, spinal cord tumors, vertebral Use for treating lower urinary tract diseases and conditions (such as lower urinary tract obstruction), lower urinary tract inflammatory diseases and conditions (such as dysuria and frequent urination), pancreatic diseases and conditions, abnormal angiogenesis-related diseases and conditions (such as arterial occlusion), scleroderma, brain-related diseases and conditions (such as cerebral infarction and cerebral hemorrhage), neuropathic pain and peripheral neuropathy, eye diseases and conditions (such as age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreoretinopathy (PVR), cicatricial pemphigoid, and scars after glaucoma filtration surgery), characterized in that a therapeutically effective amount of the compound according to any one of claims 1 to 7 or a pharmacologic acceptable salt thereof, or the composition according to claim 8 is administered to a patient. [Claim 11] 11. The use of claim 10, wherein the disease or condition is renal fibrosis, pulmonary fibrosis, hepatic fibrosis, arterial fibrosis, or systemic sclerosis.
Claims
1. Formula (I) or (II): 【Chemistry 1】 [In the formula, X is independently -C(O)-, -CH 2 - and -CH 2 C(O)-; Ar 1 is independently phenyl or naphthyl; where each ring is selected from the group consisting of cyano, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, and C 1-4 substituted with 1 to 5 substituents selected from haloalkoxy; R 1 is independently 1-4 Alkyl, and C 1-4 haloalkyl; R 2 are independently H or C 1-4 is alkyl; R 3 are independently 2 , -(CH 2 ) 1-2 Ar 2 , and -CH 2 CH 2 NR 4 Ar 2 Selected from; Ar 2 independently contains 9 to 10 ring atoms, where 1 to 4 ring atoms are each independently selected from N, N(R 5 ), O, and S; each ring is selected from OH, cyano, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, N(C 1-4 Alkyl) 2 , -SO 2 (C 1-4 Alkyl), -OPh, -OBn, C 3-6 Cycloalkyl; and cyano, halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, -NH 2 , -NH(C 1-4 alkyl), and -N(C 1-4 Alkyl) 2 phenyl substituted with 0-1 substituents selected from; R 4 are independently H or C 1-4 is alkyl; and R 5 are independently H or C 1-4 is alkyl] or a pharma- ceutically acceptable salt thereof.
2. The compound has formula (Ia): 【Chemistry 3】 2. The compound of claim 1, wherein:
3. Ar 1 is independently phenyl or naphthyl; wherein each ring is selected from the group consisting of cyano, halogen, C 1-4 Alkyl, and C 1-4 substituted with 1 to 3 substituents selected from alkoxy; R 1 But independently, C 1-4 is alkyl; and Ar 2 are independently benzothiophenyl, benzothiazolyl, N-(C 1-4 each ring is selected from OH, cyano, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, N(C 1-4 Alkyl) 2 , -SO 2 (C 1-4 3. The compound of claim 1 or claim 2, or a pharma- ceutically acceptable salt thereof, substituted with 0 to 4 substituents selected from -alkyl, -OPh, and -OBn.
4. Ar 1 But independently, 【Chemistry 5】 4. The compound according to any one of claims 1 to 3, selected from: or a pharma- ceutically acceptable salt thereof.
5. R 3 But independently, Ar 2 , -(CH 2 ) 1-2 Ar 2 , and -CH 2 CH 2 NR 4 Ar 2 Selected from; Ar 2 But independently, 【Chemistry 6】 5. The compound according to any one of claims 1 to 4, selected from: or a pharma- ceutically acceptable salt thereof.
6. R 1 But independently, CH 3 and; R 2 However, independently, H, CH 3 , -CH 2 CH 3 , and -CH(CH 3 ) 2 Selected from; and R 4 are independently H or CH 3 6. The compound according to any one of claims 1 to 5, wherein:
7. , and 2. The compound of claim 1, selected from:
8. A composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers.
9. 9. The composition of claim 8 for use as a medicament.
10. fibrosis of organs (such as liver, kidney, lung, heart and skin), liver diseases and conditions (such as acute hepatitis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, liver regeneration failure, non-alcoholic steatohepatitis (NASH), liver dysfunction and liver blood flow disorder), cell proliferation diseases and cancer diseases (such as solid tumors, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL) and infiltrative metastasis of cancer cells), inflammatory diseases and conditions (such as psoriasis, nephropathy and pneumonia), gastrointestinal diseases and conditions (such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and abnormal pancreatic secretion), kidney diseases and conditions, urinary tract-related diseases and conditions (such as benign prostatic hyperplasia, 8. A pharmaceutical composition comprising the compound according to any one of claims 1 to 7 or a pharmacologic acceptable salt thereof for treating neurogenic bladder-related diseases, spinal tumors, herniated discs, spinal canal stenosis, and diabetes-related conditions, lower urinary tract diseases and conditions (such as lower urinary tract obstruction), lower urinary tract inflammatory diseases and conditions (such as dysuria and frequent urination), pancreatic diseases and conditions, abnormal angiogenesis-related diseases and conditions (such as arterial occlusion), scleroderma, brain-related diseases and conditions (such as cerebral infarction and cerebral hemorrhage), neuropathic pain and peripheral neuropathy, eye diseases and conditions (such as age-related macular degeneration (AMD), diabetic retinopathy, proliferative vitreoretinopathy (PVR), cicatricial pemphigoid, and scars after glaucoma filtration surgery).
11. 11. The pharmaceutical composition of claim 10, wherein the disease or condition is renal fibrosis, pulmonary fibrosis, hepatic fibrosis, arterial fibrosis, or systemic sclerosis.
Citation Information
Patent Citations
Novel galactoside inhibitors of galectins
JP2018503660A
Compounds for the prevention and treatment of diseases and the use thereof
WO2018209255A1
Compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2018209276A1
Small molecule inhibitors of galectin-3
WO2019067702A1
